Carl Dambkowski Sells 26,400 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $132.60, for a total value of $3,500,640.00. Following the transaction, the insider owned 179,248 shares in the company, valued at $23,768,284.80. This trade represents a 12.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, June 3rd, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The shares were sold at an average price of $78.71, for a total value of $432,905.00.
• On Wednesday, May 6th, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $84.14, for a total value of $462,770.00.
• On Wednesday, April 1st, Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock. The stock was sold at an average price of $84.84, for a total transaction of $466,620.00.

Apogee Therapeutics Stock Performance

Shares of APGE opened at $132.68 on Friday. Apogee Therapeutics Inc. has a twelve month low of $34.34 and a twelve month high of $133.16. The firm’s 50 day moving average price is $88.55 and its two-hundred day moving average price is $79.67. The firm has a market cap of $8.21 billion, a P/E ratio of -30.64 and a beta of 0.62.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.01. On average, sell-side analysts anticipate that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on APGE shares. Citigroup downgraded Apogee Therapeutics from a “buy” rating to a “neutral” rating and lifted their price target for the company from $125.00 to $135.00 in a research note on Tuesday. Stifel Nicolaus reiterated a “hold” rating and set a $135.00 price objective (up from $133.00) on shares of Apogee Therapeutics in a report on Wednesday. Craig Hallum set a $135.11 target price on Apogee Therapeutics and gave the company a “hold” rating in a research report on Monday. BTIG Research restated a “buy” rating and issued a $137.00 target price on shares of Apogee Therapeutics in a research note on Wednesday, May 27th. Finally, Truist Financial reduced their price target on Apogee Therapeutics from $83.00 to $81.00 and set a “hold” rating for the company in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Apogee Therapeutics has a consensus rating of “Hold” and a consensus price target of $121.25.

Hedge Funds Weigh In On Apogee Therapeutics

Large investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. grew its holdings in shares of Apogee Therapeutics by 189,522.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company’s stock valued at $206,246,000 after acquiring an additional 2,731,015 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Apogee Therapeutics by 324.4% during the fourth quarter. Janus Henderson Group PLC now owns 2,062,604 shares of the company’s stock worth $155,697,000 after acquiring an additional 1,576,626 shares in the last quarter. Perceptive Advisors LLC boosted its position in Apogee Therapeutics by 72.4% during the fourth quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company’s stock valued at $175,918,000 after purchasing an additional 978,662 shares during the last quarter. Wellington Management Group LLP grew its stake in Apogee Therapeutics by 24.1% in the third quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company’s stock valued at $187,673,000 after purchasing an additional 917,991 shares in the last quarter. Finally, UBS Group AG grew its stake in Apogee Therapeutics by 646.1% in the third quarter. UBS Group AG now owns 799,465 shares of the company’s stock valued at $31,763,000 after purchasing an additional 692,308 shares in the last quarter. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Apogee Therapeutics News Roundup

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Apogee’s proposed sale to AbbVie for $135.11 per share continues to anchor the stock near deal value and provides clear upside support for investors. Article Title
• Neutral Sentiment: Stifel kept a hold rating and raised its price target to $135, signaling the shares are already trading close to fair value under the transaction terms. Article Title
• Neutral Sentiment: Mizuho downgraded APGE to hold but lifted its target to $135, reflecting limited additional upside beyond the deal price. Article Title
• Neutral Sentiment: Short-interest data showed no meaningful change in bearish positioning, offering little new signal for traders. Article Title
• Negative Sentiment: Insider sales by CEO Michael Henderson and insider Carl Dambkowski may add some pressure, even though both transactions were made under pre-arranged 10b5-1 plans. Article Title
• Negative Sentiment: A law firm launched an investigation into whether the proposed sale price and process were adequate, creating a legal overhang that could complicate the deal. Article Title

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.